NUVB vs. LYEL, ATXS, OLMA, MLYS, VERV, CVAC, ZYME, KRRO, SIGA, and SLN
Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Lyell Immunopharma (LYEL), Astria Therapeutics (ATXS), Olema Pharmaceuticals (OLMA), Mineralys Therapeutics (MLYS), Verve Therapeutics (VERV), CureVac (CVAC), Zymeworks (ZYME), Korro Bio (KRRO), SIGA Technologies (SIGA), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
Lyell Immunopharma (NASDAQ:LYEL) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 24.0% of Lyell Immunopharma shares are owned by insiders. Comparatively, 36.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Nuvation Bio received 18 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 71.43% of users gave Nuvation Bio an outperform vote while only 54.55% of users gave Lyell Immunopharma an outperform vote.
Nuvation Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -180,486.14%. Lyell Immunopharma's return on equity of -12.21% beat Nuvation Bio's return on equity.
Nuvation Bio has lower revenue, but higher earnings than Lyell Immunopharma. Nuvation Bio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvation Bio had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Nuvation Bio and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.15 beat Nuvation Bio's score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.
Lyell Immunopharma has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Lyell Immunopharma currently has a consensus target price of $5.50, indicating a potential upside of 157.01%. Nuvation Bio has a consensus target price of $6.60, indicating a potential upside of 146.27%. Given Nuvation Bio's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Nuvation Bio.
Summary
Nuvation Bio beats Lyell Immunopharma on 13 of the 17 factors compared between the two stocks.
Get Nuvation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvation Bio Competitors List
Related Companies and Tools
